Interstitial lung diseases (ILDs) represent a diverse group of over 200 lung disorders characterized by inflammation and fibrosis of the alveolar walls. This article provides a comprehensive overview of the causes, symptoms, and treatment strategies for ILDs.
ILDs may be idiopathic or associated with various factors such as occupational and environmental exposures, systemic diseases, and certain medications. Smoking, age, and a family history of ILDs are other significant risk factors.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Other symptoms may include fatigue, weight loss, and clubbing. The physical examination may reveal inspiratory crackles and signs of pulmonary hypertension in advanced stages.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, providing detailed images of the lung parenchyma. Pulmonary function tests reveal a restrictive pattern with reduced diffusing capacity for carbon monoxide. In certain cases, a lung biopsy may be necessary to establish a definitive diagnosis.
Management of ILDs involves addressing the underlying cause, if identified, and slowing disease progression. Pharmacologic therapy includes corticosteroids and immunosuppressive agents. Antifibrotic drugs such as pirfenidone and nintedanib have shown efficacy in idiopathic pulmonary fibrosis. Lung transplantation may be considered in selected patients with advanced disease.
Given the chronic and progressive nature of ILDs, palliative care focusing on symptom management and improving quality of life is essential. The prognosis varies widely depending on the specific type of ILD, ranging from relatively benign to rapidly progressive and fatal.
Interstitial lung diseases are complex disorders requiring a comprehensive approach to diagnosis and management. Understanding the diverse etiologies, recognizing the clinical manifestations, and being familiar with the current treatment strategies are crucial for optimal patient care.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation